康华生物
(300841)
| 流通市值：54.62亿 | | | 总市值：59.68亿 |
| 流通股本：1.19亿 | | | 总股本：1.30亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 172,451,817.58 | 1,165,000,864.15 | 840,062,581.82 | 483,918,966.75 |
| 营业总成本 | 140,114,140.64 | 895,140,732.6 | 613,116,128.08 | 348,216,470.57 |
| 其他经营收益 | | | | |
| 营业利润 | 29,678,844.43 | 259,870,340.92 | 221,700,491.66 | 125,538,134.91 |
| 利润总额 | 29,543,013.64 | 259,743,208.05 | 221,653,998.38 | 125,497,894.3 |
| 净利润 | 27,363,417.47 | 219,897,935.04 | 189,110,720.76 | 114,520,580.49 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 27,363,417.47 | 219,897,935.04 | 189,110,720.76 | 114,520,580.49 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,434,038,938.98 | 2,523,195,286.17 | 2,416,046,526.85 | 2,314,785,612.61 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,472,277,867.15 | 1,486,577,781.58 | 1,521,449,718.36 | 1,522,115,413.94 |
| 资产总计 | 3,906,316,806.13 | 4,009,773,067.75 | 3,937,496,245.21 | 3,836,901,026.55 |
| 流动负债: | | | | |
| 流动负债合计 | 308,545,613.34 | 439,320,635.58 | 412,879,034.8 | 395,815,671.04 |
| 非流动负债: | | | | |
| 非流动负债合计 | 32,948,043 | 32,992,699.85 | 17,944,692.37 | 9,002,977.74 |
| 负债合计 | 341,493,656.34 | 472,313,335.43 | 430,823,727.17 | 404,818,648.78 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,564,823,149.79 | 3,537,459,732.32 | 3,506,672,518.04 | 3,432,082,377.77 |
| 股东权益合计 | 3,564,823,149.79 | 3,537,459,732.32 | 3,506,672,518.04 | 3,432,082,377.77 |
| 负债和股东权益合计 | 3,906,316,806.13 | 4,009,773,067.75 | 3,937,496,245.21 | 3,836,901,026.55 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 256,380,689.1 | 1,297,220,894.23 | 874,351,713.06 | 533,225,043.15 |
| 经营活动现金流出小计 | 235,508,012.28 | 917,510,609.19 | 720,626,508.18 | 467,902,555.43 |
| 经营活动产生的现金流量净额 | 20,872,676.82 | 379,710,285.04 | 153,725,204.88 | 65,322,487.72 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 452,172,423.21 | 1,028,132,880.28 | 520,388,216.84 | 260,133,867.66 |
| 投资活动现金流出小计 | 1,000,568,041.22 | 880,785,928.9 | 608,071,836.07 | 343,586,357.51 |
| 投资活动产生的现金流量净额 | -548,395,618.01 | 147,346,951.38 | -87,683,619.23 | -83,452,489.85 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | 179,793,800 | 149,793,800 | 139,793,800 |
| 筹资活动现金流出小计 | 110,187,740.04 | 363,215,261.39 | 322,471,527.63 | 310,225,978.98 |
| 筹资活动产生的现金流量净额 | -110,187,740.04 | -183,421,461.39 | -172,677,727.63 | -170,432,178.98 |
| 汇率变动对现金及现金等价物的影响 | -14,104.09 | 43,743.3 | 55,411.6 | 62,092.36 |
| 现金及现金等价物净增加额 | -637,724,785.32 | 343,679,518.33 | -106,580,730.38 | -188,500,088.75 |
| 期末现金及现金等价物余额 | 505,668,023.38 | 1,143,392,808.7 | 693,132,559.99 | 611,213,201.62 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 343,679,518.33 | - | -188,500,088.75 |